Sanofi SA (NYSE:SNY) – Investment analysts at Jefferies Group issued their FY2019 earnings estimates for Sanofi in a report issued on Tuesday. Jefferies Group analyst J. Holford expects that the company will post earnings of $3.78 per share for the year. Jefferies Group also issued estimates for Sanofi’s FY2020 earnings at $4.14 EPS and FY2021 earnings at $4.47 EPS.
Several other brokerages have also issued reports on SNY. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Morgan Stanley lowered Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. UBS Group restated a “neutral” rating on shares of Sanofi in a research note on Monday. Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research note on Thursday, December 14th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. Sanofi currently has an average rating of “Hold” and an average target price of $51.50.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $1.00 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.00. Sanofi had a return on equity of 25.19% and a net margin of 25.44%.
Several hedge funds have recently added to or reduced their stakes in the company. Cullinan Associates Inc. grew its stake in shares of Sanofi by 15.1% in the 4th quarter. Cullinan Associates Inc. now owns 91,150 shares of the company’s stock valued at $3,919,000 after purchasing an additional 11,950 shares during the period. E&G Advisors LP grew its stake in shares of Sanofi by 6.3% in the 4th quarter. E&G Advisors LP now owns 23,625 shares of the company’s stock valued at $1,016,000 after purchasing an additional 1,400 shares during the period. Clean Yield Group grew its stake in shares of Sanofi by 52.4% in the 4th quarter. Clean Yield Group now owns 61,352 shares of the company’s stock valued at $2,638,000 after purchasing an additional 21,095 shares during the period. BLB&B Advisors LLC grew its stake in shares of Sanofi by 36.8% in the 4th quarter. BLB&B Advisors LLC now owns 5,573 shares of the company’s stock valued at $240,000 after purchasing an additional 1,500 shares during the period. Finally, Beacon Financial Group grew its stake in shares of Sanofi by 12.5% in the 4th quarter. Beacon Financial Group now owns 105,488 shares of the company’s stock valued at $4,536,000 after purchasing an additional 11,761 shares during the period. Institutional investors own 9.08% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://sportsperspectives.com/2018/01/18/jefferies-group-comments-on-sanofi-sas-fy2019-earnings-sny.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.